|By Marketwired .||
|September 24, 2013 07:00 AM EDT||
MIAMI, FL -- (Marketwired) -- 09/24/13 -- Seniors throughout Florida with severe vision loss due to macular degeneration now have hope of restored sight, thanks to a tiny telescope surgically implanted in a patient's eye. Teams of doctors and low vision specialists in Jacksonville, Miami, Orlando, Pensacola and Sarasota are among the first in the nation to offer the CentraSight® treatment program, which features the first ever telescope implant for patients with end-stage age-related macular degeneration (AMD), the most advanced form of AMD and the leading cause of blindness in older Americans. More than 15 million Americans are affected by some form of AMD.
The telescope implant is the only surgical option that improves visual acuity by reducing the impact of the central vision blind spot caused by end-stage AMD. Smaller than a pea, it uses micro-optical technology to magnify images, which would normally be seen in one's "straight ahead," or central, vision. The images are projected onto the healthy portion of the retina not affected by the disease, making it possible for patients to see or discern the central vision object of interest.
Patients with end-stage AMD have a central blind spot. This vision loss makes it difficult or impossible to see faces, read, and perform everyday activities such as watching TV, preparing meals, and self-care. The telescope implant can improve patients' vision so they can see the things that are important to them, increase their independence, and re-engage in everyday activities. It also may help patients in social settings as it may allow them to recognize faces and see the facial expressions of family and friends.
The device is FDA approved and the cost for the telescope implant and visits associated with the treatment program are Medicare eligible. There are currently around 60 provider teams offering the treatment throughout the U.S., Canada and Europe, and about 400 patients have received the treatment so far. CentraSight provider teams like the ones in Florida typically include a retina specialist who coordinates the treatment, a cataract and cornea surgeon who performs the surgery, and low-vision specialists who coordinate the post-surgical therapy for the patient.
Eligible candidates for the treatment must be 75 years or older, and meet several other indications for treatment. Unfortunately, the telescope implant is not a cure for end-stage AMD. As with any medical intervention, potential risks and complications exist with the telescope implant. Possible side effects include decreased vision or vision impairing corneal swelling. The risks and benefits associated with the telescope implant are discussed in the Patient Information Booklet available at www.CentraSight.com.
Patients and physicians can find more information about the telescope implant and related treatment program at www.CentraSight.com or by calling 1-877-99SIGHT.
CentraSight is the first-ever treatment program that utilizes a tiny telescope implant for end-stage age-related macular degeneration (AMD), the most advanced form of AMD and the leading cause of blindness in older Americans. Patients with end-stage AMD have a central blind spot in their vision that makes it difficult or impossible to see faces, read, and perform everyday activities. The CentraSight treatment program allows patients to see details again by implanting a tiny telescope in the eye in an outpatient procedure, then coordinating with vision specialists to help the patient learn how to use their new vision for everyday activities. For more information visit http://www.CentraSight.com/